Reflections from BIO International Convention 2024: Paving New Pathways in Biotech
As a member of Variant Bio’s business development and partnerships team, I had the privilege of attending the 2024 BIO International Convention in San Diego alongside our Chief Business Officer, Steve Bryant, and our Senior Director of Business Development & Partnerships, Prathap Kasina. BIO, a veritable melting pot of biotechnology innovation and collaboration, is a pivotal event for fostering global biotech partnerships. It provides us with an invaluable platform through which to deepen our engagement within the industry and to explore potential synergies in drug discovery and development.
This year, our focus at BIO was crystal clear: to broaden our horizons and catalyze strategic collaborations that harness our unique genomic capabilities, helping us to achieve our mission of developing life-saving therapies. We engaged in enriching discussions with leading industry organizations and innovative startups alike. These dialogues extended to explorations of potential in-licensing partnerships, target discovery alliances across metabolic, renal, immunology, and fibrotic diseases, and other strategic collaborations with industry leaders in antibody discovery and genomic research.
Beyond the meetings, the convention itself was a hub of knowledge exchange. From the latest advances in drug development to innovative therapeutic approaches, each session offered fresh insights into the rapidly evolving biotech landscape. The commitment to innovation and collaboration shared by attendees was palpable, inspiring us to think even bigger and bolder.
As we reflect on our experiences at BIO 2024, we’re invigorated by the potential collaborations that await. The path ahead is lined with opportunities to transform promising genetic insights into impactful therapies. Going forward, we are excited to fuel our strategic efforts internally with the information gathered and the learnings from this year’s conference to advance our business development goals.
